Brent Warner
2023
In 2023, Brent Warner earned a total compensation of $1.6M as President, Gene Therapy at Poseida Therapeutics, a 43% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $200,600 |
|---|---|
| Option Awards | $486,574 |
| Salary | $445,767 |
| Stock Awards | $496,330 |
| Other | $13,181 |
| Total | $1,642,452 |
Warner received $496.3K in stock awards, accounting for 30% of the total pay in 2023.
Warner also received $200.6K in non-equity incentive plan, $486.6K in option awards, $445.8K in salary and $13.2K in other compensation.
Rankings
In 2023, Brent Warner's compensation ranked 695th out of 2,912 executives tracked by ExecPay. In other words, Warner earned more than 76.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 695 out of 2,912 | 76th |
Division Manufacturing | 399 out of 1,602 | 75th |
Major group Chemicals And Allied Products | 273 out of 901 | 70th |
Industry group Drugs | 267 out of 864 | 69th |
Industry Biological Products, Except Diagnostic Substances | 88 out of 211 | 58th |
Source: SEC filing on April 25, 2024.
Warner's colleagues
We found two more compensation records of executives who worked with Brent Warner at Poseida Therapeutics in 2023.